Augmenting clozapine with sertindole: A double-blind, randomized, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 173-178

  Nielsen, Jimmi ^a   Emborg, Charlotte ^b   Gydesen, Susanne ^c   Dybbro, Jesper ^b   Aagaard, Jørgen ^b   Haderup, Karsten ^d   Glyngdal, Pia ^e   Fabricius, Susanne ^f   Thode, Dorrit ^a   Lublin, Henrik ^g   Andersen, Torben ^h   Damkier, Per ⁱ   Taylor, David ^j  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Services   (Denmark)

^d Psychiatric Hospital   (Denmark)

^e Psychiatric University Center   (Denmark)

^f Psychiatric Hospital   (Denmark)

^g University Psychiatric Center Glostrup   (Denmark)

^h Mental Health Services   (Denmark)

ⁱ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^j KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Antipsychotic; Augmentation; Clozapine; Schizophrenia; Sertindole; Treatment resistant

Indexed keywords

CLOZAPINE; GLUCOSE; PLACEBO; SERTINDOLE;

ACCOMMODATION DISORDER; ADULT; AKATHISIA; AMENORRHEA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ATTITUDE INVENTORY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DYSTONIA; EJACULATION DISORDER; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEART PALPITATION; HUMAN; HYPERKINESIA; HYPOKINESIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENORRHAGIA; MENTAL PATIENT; NAUSEA; ORGASM DISORDER; PARESTHESIA; POLYDIPSIA; POLYURIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PRURITUS; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; SALIVATION; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SLEEP TIME; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UDVALG FOR KLINISKE UNDERSOGELSER; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION QUALITY OF LIFE BRIEF;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84857873303     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318248dfb8     Document Type: Article

References (51)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
2. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
3. Conley RR, Kelly DL, Richardson CM, et al. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol. 2003;23:668-671. (Pubitemid 37443202)
4. Essali A, Al-Haj Haasan N, Li C, et al. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;1:CD000059.
5. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91. (Pubitemid 36070868)
6. Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006;63:622-629. (Pubitemid 43848293)
7. Peacock L, Solgaard T, Lublin H, et al. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl). 1996;124:188-196.
8. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28:995-1003.
9. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576-580.
10. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother. 2007;7:829-839. (Pubitemid 47037723)
11. Nielsen J, Foldager L, Meyer JM. Increased use of antibiotics in patients treated with clozapine. Eur Neuropsychopharmacol. 2009;19:483-486.
12. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66:1116-1121. (Pubitemid 41442277)
13. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology. 2010;35:1997-2004.
14. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151:1744-1752. (Pubitemid 24370894)
15. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry. 1994;55:44-49. (Pubitemid 24081820)
16. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry. 1998;10:113-115. (Pubitemid 28495145)
17. Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. Australas Psychiatry. 2004;12:74-76. (Pubitemid 38488964)
18. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472-482. (Pubitemid 43200298)
19. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162:130-136. (Pubitemid 40095682)
20. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry. 1997;171:569-573. (Pubitemid 27527329)
21. Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65:510-517.
22. Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92:90-94. (Pubitemid 46561216)
23. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychoticVa meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand. 2009;119:419-425.
24. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology. 2006;31:1991-2001.
25. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(suppl 2):S12-S21.
26. Lieberman JA 3rd. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry. 2004;6:20-23.
27. Chengappa KN, Pollock BG, Parepally H, et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol. 2000;20:311-316. (Pubitemid 30318359)
28. Shankar BR. Clozapine-induced delirium. J Neuropsychiatry Clin Neurosci. 2008;20:239-240.
29. Centorrino F, Albert MJ, Drago-Ferrante G, et al. Delirium during clozapine treatment: incidence and associated risk factors. Pharmacopsychiatry. 2003;36:156-160. (Pubitemid 37041336)
30. Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69:759-768. (Pubitemid 351838685)
31. Nielsen J, Damkier P, Lublin H, et al. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123:411-422.
32. Murdoch D, Keating GM. Sertindole: a review of its use in schizophrenia. CNS Drugs. 2006;20:233-255.
33. Thomas SH, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the Sertindole Cohort Prospective Study (SCoP). Acta Psychiatr Scand. 2010;122:345-355.
34. Lindstrom E, Farde L, Eberhard J, et al. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol. 2005;8:615-629. (Pubitemid 41400893)
35. Nielsen J, Andersen MP, Graff C, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand. 2010;121:385-388.
36. Nielsen J, Graff C, Hardahl T, et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol. 2009;19:702-707.
37. Kane JM, Potkin SG, Daniel DG, et al. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72:194-204.
38. Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006;21:49-56. (Pubitemid 43175123)
39. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry. 1997;154:782-791. (Pubitemid 27230100)
40. Spina E, Zoccali R. Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert Opin Drug Metab Toxicol. 2008;4:629-638. (Pubitemid 351890743)
41. Casey DE. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys. Psychopharmacology (Berl). 1996;124:134-140. (Pubitemid 26112781)
42. Idris N, Neill J, Grayson B, et al. Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl). 2010;208:23-36.
43. Skarsfeldt T, Perregaard J. Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur J Pharmacol. 1990;182:613-614. (Pubitemid 20260788)
44. Steinert T, Hauger B, Eckardt J, et al. Clinical observations of sertindole in 53 hospitalised patients with psychotic disorders. Clin Drug Investig. 2005;25:79-83. (Pubitemid 40740195)
45. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100. (Pubitemid 17115352)
46. Fritze J, Bandelow B. The QT interval and the atypical antipsychotic, sertindole. Int J Psychiatry Clin Pract. 1998;2:265-273. (Pubitemid 29023490)
47. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13:1115-1125.
48. Nielsen J, le Quach P, Emborg C, et al. 10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand. 2010;122:356-366.
49. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005;66:63-72.
50. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93:457-462.
51. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006;21:99-103. (Pubitemid 43740317)